(Q38118056)

29 August 2017

title

Sequencing systemic therapies in metastatic castration-resistant prostate cancer (English)

1 reference

29 August 2017

1 reference

Jane Jijun Liu

1

1 reference

29 August 2017

Jingsong Zhang

series ordinal

2

1 reference

29 August 2017

publication date

1 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

20

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

181-187

1 reference

29 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Characterising the castration-resistant prostate cancer population: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Management of advanced prostate cancer after first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Targeting continued androgen receptor signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000306

10.1177/107327481302000306

21 January 2018

Identifiers

DOI

0 references

1 reference